Antiviral Peptides (AVPs) of Marine Origin As Propitious Therapeutic Drug Candidates for the Treatment of Human Viruses

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 May 14

PMID 35565968

Authors

Linda Sukmarini

Affiliations

Soon will be listed here.

Abstract

The marine environment presents a favorable avenue for potential therapeutic agents as a reservoir of new bioactive natural products. Due to their numerous potential pharmacological effects, marine-derived natural products-particularly marine peptides-have gained considerable attention. These peptides have shown a broad spectrum of biological functions, such as antimicrobial, antiviral, cytotoxic, immunomodulatory, and analgesic effects. The emergence of new virus strains and viral resistance leads to continuing efforts to develop more effective antiviral drugs. Interestingly, antimicrobial peptides (AMPs) that possess antiviral properties and are alternatively regarded as antiviral peptides (AVPs) demonstrate vast potential as alternative peptide-based drug candidates available for viral infection treatments. Hence, AVPs obtained from various marine organisms have been evaluated. This brief review features recent updates of marine-derived AVPs from 2011 to 2021. Moreover, the biosynthesis of this class of compounds and their possible mechanisms of action are also discussed. Selected peptides from various marine organisms possessing antiviral activities against important human viruses-such as human immunodeficiency viruses, herpes simplex viruses, influenza viruses, hepatitis C virus, and coronaviruses-are highlighted herein.

Citing Articles

Anti-Herpetic Activity of Killer Peptide (KP): An In Vitro Study.

Sala A, Ricchi F, Giovati L, Conti S, Ciociola T, Cermelli C Int J Mol Sci. 2024; 25(19).

PMID: 39408931 PMC: 11477280. DOI: 10.3390/ijms251910602.

Structural and Dynamical Basis of VP35-RBD Inhibition by Marine Fungi Compounds to Combat Marburg Virus Infection.

Alawam A, Alawam H, Alshahrani M, Alwethaynani M, Alneghery L, Alamri M Mar Drugs. 2024; 22(1).

PMID: 38248659 PMC: 10820117. DOI: 10.3390/md22010034.

Marine Invertebrate Antimicrobial Peptides and Their Potential as Novel Peptide Antibiotics.

Guryanova S, Balandin S, Belogurova-Ovchinnikova O, Ovchinnikova T Mar Drugs. 2023; 21(10).

PMID: 37888438 PMC: 10608444. DOI: 10.3390/md21100503.

Hylin-a1: A Pan-Inhibitor against Emerging and Re-Emerging Respiratory Viruses.

Chianese A, Zannella C, Monti A, Doti N, Sanna G, Manzin A Int J Mol Sci. 2023; 24(18).

PMID: 37762191 PMC: 10531407. DOI: 10.3390/ijms241813888.

Review and perspective on bioinformatics tools using machine learning and deep learning for predicting antiviral peptides.

Lefin N, Herrera-Belen L, Farias J, Beltran J Mol Divers. 2023; 28(4):2365-2374.

PMID: 37626205 DOI: 10.1007/s11030-023-10718-3.

References

Anderegg R, Biemann K, BUCHI G, Cushman M . Malformin C, a new metabolite of Aspergillus niger. J Am Chem Soc. 1976; 98(11):3365-70. DOI: 10.1021/ja00427a051. View

Lu Z, Wagoner R, Harper M, Baker H, Hooper J, Bewley C . Mirabamides E-H, HIV-inhibitory depsipeptides from the sponge Stelletta clavosa. J Nat Prod. 2011; 74(2):185-93. PMC: 3072293. DOI: 10.1021/np100613p. View

Tianero M, Donia M, Young T, Schultz P, Schmidt E . Ribosomal route to small-molecule diversity. J Am Chem Soc. 2011; 134(1):418-25. PMC: 3268757. DOI: 10.1021/ja208278k. View

Lissabet J, Belen L, Farias J . AntiVPP 1.0: A portable tool for prediction of antiviral peptides. Comput Biol Med. 2019; 107:127-130. PMC: 7094449. DOI: 10.1016/j.compbiomed.2019.02.011. View

Kobbe B, Cushman M, Wogan G, DEMAIN A . Production and antibacterial activity of malforming C, a toxic metabolite of Aspergillus niger. Appl Environ Microbiol. 1977; 33(4):996-7. PMC: 170807. DOI: 10.1128/aem.33.4.996-997.1977. View

Wang Z, Wang G . APD: the Antimicrobial Peptide Database. Nucleic Acids Res. 2003; 32(Database issue):D590-2. PMC: 308759. DOI: 10.1093/nar/gkh025. View

Lovato E, Barboza L, Wietzikoski S, de Souza A, Auth P, Gasparotto Junior A . Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Curr Pharm Des. 2020; 27(1):115-126. DOI: 10.2174/1381612826666200707121636. View

Gao B, Zhao D, Li L, Cheng Z, Guo Y . Antiviral Peptides with in vivo Activity: Development and Modes of Action. Chempluschem. 2021; 86(12):1547-1558. DOI: 10.1002/cplu.202100351. View

Luo M, Zang R, Wang X, Chen Z, Song X, Ju J . Natural Hydroxamate-Containing Siderophore Acremonpeptides A-D and an Aluminum Complex of Acremonpeptide D from the Marine-Derived SCSIO 115. J Nat Prod. 2019; 82(9):2594-2600. DOI: 10.1021/acs.jnatprod.9b00545. View

10.

Lu Z, Harper M, Pond C, Barrows L, Ireland C, Wagoner R . Thiazoline peptides and a tris-phenethyl urea from Didemnum molle with anti-HIV activity. J Nat Prod. 2012; 75(8):1436-40. PMC: 4176947. DOI: 10.1021/np300270p. View

11.

Vilas Boas L, Campos M, Berlanda R, de Carvalho Neves N, Franco O . Antiviral peptides as promising therapeutic drugs. Cell Mol Life Sci. 2019; 76(18):3525-3542. PMC: 7079787. DOI: 10.1007/s00018-019-03138-w. View

12.

Jang W, Jeon S, Kim S, Lee S . Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. Proc Natl Acad Sci U S A. 2021; 118(30). PMC: 8325362. DOI: 10.1073/pnas.2024302118. View

13.

Kalhotra P, Chittepu V, Osorio-Revilla G, Gallardo-Velazquez T . Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors. Molecules. 2021; 26(4). PMC: 7916619. DOI: 10.3390/molecules26040936. View

14.

Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M . Synthetic therapeutic peptides: science and market. Drug Discov Today. 2009; 15(1-2):40-56. DOI: 10.1016/j.drudis.2009.10.009. View

15.

Heydari H, Golmohammadi R, Mirnejad R, Tebyanian H, Fasihi-Ramandi M, Moosazadeh Moghaddam M . Antiviral peptides against Coronaviridae family: A review. Peptides. 2021; 139:170526. PMC: 7931737. DOI: 10.1016/j.peptides.2021.170526. View

16.

Sagar S, Kaur M, Minneman K . Antiviral lead compounds from marine sponges. Mar Drugs. 2010; 8(10):2619-38. PMC: 2992996. DOI: 10.3390/md8102619. View

17.

Raihan T, Rabbee M, Roy P, Choudhury S, Baek K, Azad A . Microbial Metabolites: The Emerging Hotspot of Antiviral Compounds as Potential Candidates to Avert Viral Pandemic Alike COVID-19. Front Mol Biosci. 2021; 8:732256. PMC: 8452873. DOI: 10.3389/fmolb.2021.732256. View

18.

Vishvakarma V, Singh M, Jain P, Kumari K, Singh P . Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations. Amino Acids. 2021; 54(2):205-213. PMC: 8607790. DOI: 10.1007/s00726-021-03098-1. View

19.

Chi X, Niu Y, Cheng M, Liu X, Feng Y, Zheng F . Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain. Sci Rep. 2016; 6:25224. PMC: 4848495. DOI: 10.1038/srep25224. View

20.

Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G . Viral Hepatitis: Etiology, Epidemiology, Transmission, Diagnostics, Treatment, and Prevention. Infect Dis Clin North Am. 2019; 33(4):1045-1062. DOI: 10.1016/j.idc.2019.08.004. View